v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net loss $ (15,750) $ (12,968)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation expense 2,219 2,687
Depreciation and amortization 2,587 2,837
Noncash operating lease cost 398 337
Amortization of discount on short-term investments (1,084) (723)
Other (377) 199
Changes in operating assets and liabilities    
Accounts receivable [1] (2,833) 6,385
Inventory and other deferred costs 1,017 1,707
Prepaid expenses and other assets (1,230) (203)
Accounts payable [2] 2,013 (5,637)
Accrued and other current liabilities [2] (2,742) (7,836)
Contract liabilities (1,136) (1,593)
Operating lease liabilities (993) (840)
Other long-term liabilities [2] (50)  
Net cash used in operating activities (17,961) (20,413)
Cash flows from investing activities:    
Purchases of available-for-sale debt securities (64,281) (29,095)
Proceeds from maturities of available-for-sale debt securities 44,250 35,500
Purchases of property and equipment (2,511) (104)
Net cash (used in) provided by investing activities (22,542) 6,301
Cash flows from financing activities:    
Proceeds from sales of common stock under ATM facility, net of commissions 17,782 1,437
Payment of costs related to Tempus and Merck Investment Agreements (106)  
Proceeds from loans 2,587  
Repayments of loans (308) (308)
Proceeds from issuance of common stock under equity incentive plans 132  
Net cash provided by financing activities 20,087 1,129
Effect of exchange rates on cash, cash equivalents and restricted cash 2 (20)
Net change in cash, cash equivalents and restricted cash (20,414) (13,003)
Cash, cash equivalents and restricted cash, beginning of period 93,205 58,774
Cash, cash equivalents and restricted cash, end of period 72,791 45,771
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:    
Cash and cash equivalents 71,001 43,981
Restricted cash, included in other long-term assets 1,790 1,790
Total cash, cash equivalents and restricted cash $ 72,791 45,771
Tempus Warrants    
Adjustments to reconcile net loss to net cash used in operating activities    
Noncash gain related to liability classified Tempus Warrants   $ (4,765)
[1] Includes a change in related party receivable of $1.9 million for the three months ended March 31, 2025.
[2] Includes a change in related party liabilities of $1.0 million for the three months ended March 31, 2025